效应与参数分析

数据集获取（Figshare）

• 源站标题：Effects and parameters analysis.
• DOI：10.1371/journal.pone.0332599.t002
• 发布日期：2025-09-26
• 文件数：1 个
• 文件总体积：13.82 KB
• 源站页面：https://plos.figshare.com/articles/dataset/Effects_and_parameters_analysis_/30222781

命令行下载

curl -L -o "Table 2.xls" "https://ndownloader.figshare.com/files/58306609"

文件清单

• Table 2.xls（13.82 KB）

文件总体积 13.82 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Background
To date, no meta-analysis has studied the general outcomes of personalized cancer drug therapy with a focus on current targeted, immunotherapy, and multi-agent phase II clinical trials.
Objective
We conducted a systematic review and meta-analysis to provide a comprehensive overview of outcomes in patients undergoing personalized genomics-based versus non-personalized treatment in oncology.
Data source
We searched for publications in PubMed, dedicated to specific cancer drug treatment and phase II clinical trials, and published from 2010 to 2021. The search dates were from 20.10.23 to 20.11.23. The final data check was on 20.12.23.
Selection criteria
Studies of chemotherapy, immunotherapy, and targeted therapy were included. Only trials, including adults (more than 18 y.o.) were selected. The personalization was evaluated based on genetic markers and study design.
Data collection and analysis
The study was performed following PRISMA guidelines. Two reviewers worked independently to select studies and arms, and one checked the results. Three reviewers extracted the data, and another reviewer independently checked it. The proportional meta-analysis, random-effects model, and meta-regression were employed to evaluate the effects of genomics-based personalization and other study design parameters (randomization, multi-central protocol, pre-treatment, therapy type, number of patients per arm, and journal impact factor) on the treatment outcomes. Mann-Whitney was employed to compare survival medians, p Results
We evaluated 50 studies, having 81 arms and 6536 patients. Response Rate (RR) and 1-year Progression-Free Survival (PFS) were significantly higher in personalized arms (p = 0.009 and p = 0.011). Medians of PFS and Overall Survival (OS) were also higher in personalized arms (p = 0.018 and p = 0.032). Proportional meta-analysis and meta-regression detected a significant positive association between personalized treatment and RR (p = 0.037). The same results were obtained for 1-year PFS and OS rates (p = 0.043 and p = 0.022). Previous drug treatment, type of therapy (targeted therapy/immunotherapy/cytotoxic chemotherapy), study design, and journal impact

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.1371/journal.pone.0332599.t002（source: https://plos.figshare.com/articles/dataset/Effects_and_parameters_analysis_/30222781）。